Item 9A. Controls and Procedures
Item 9A. Controls and Procedures.
Limitations on effectiveness of controls and procedures
In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Evaluation of disclosure controls and procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this Form 10-K, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, due to the material weaknesses described below, our disclosure controls and procedures were not effective at the reasonable assurance level as of December 31, 2023.
Management’s annual report on internal control over financial reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act). Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with GAAP.
Our management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth in “Internal Control – Integrated Framework (2013)” issued by the Committee of Sponsoring Organizations of the Treadway Commission.
Based on this assessment, our management concluded that our internal control over financial reporting was not effective as of December 31, 2023 due to the material weaknesses in our internal control over financial reporting described below.
A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.
As previously reported, management has identified the following material weaknesses in the Company’s internal control over financial reporting, which continued to exist as of December 31, 2023:
• We did not have adequate policies and procedures or sufficient qualified resources with appropriate technical knowledge to maintain effective internal controls over the accounting related to significant accounts and related financial statement disclosures;
• We did not design and implement a sufficient risk assessment process to identify and assess risks impacting internal control over financial reporting;
• We had ineffective evaluation and determination as to whether the components of internal control were present and functioning;
• We did not design and implement effective information technology general controls in the areas of user access related to certain information technology systems that support our financial reporting process;
• We did not maintain sufficient segregation of duties over the performance of control activities for financial close and reporting, including over the review of account reconciliations and journal entries;
• We did not design and maintain effective management review controls at a sufficient level of precision over all financial statement areas; and
P3 Health Partners Inc. | 2023 Form 10-K | 113
Table of Contents
• We did not design and maintain effective controls at a sufficient level of precision over the estimation of claims expense and payable including controls over the review of historical claims data, including the completeness and accuracy of data used to determine the financial statement amounts.
Remediation activities
In response to these material weaknesses, with oversight from the Audit Committee of the Board of Directors, we have continued to implement significant changes to improve our internal control structure. Specifically, we have:
• engaged an external advisor to assist with documenting internal controls, including (i) enhancing controls to ensure proper communication of critical information, review and approvals, (ii) evaluating effectiveness of internal controls, and (iii) assisting with the remediation of deficiencies and training of personnel, as necessary;
• formalized enhanced policies, procedures, and documentation for significant areas of accounting, including each area where a material weakness was identified;
• hired qualified accounting, financial reporting, information technology, and other key management personnel with public company experience;
• implemented a revised information technology general controls framework that is customized to our application landscape and information risks inherent in the financial reporting process;
• implemented user access reviews across all significant information technology applications, standardized and improved the change management process to mitigate execution risks, and provided training to control owners; and
• designed a segregation of duties risk framework in order to establish a technology-enabled process to identify and evaluate user roles to mitigate segregation of duties conflicts.
We are committed to maintaining a strong internal control environment. We are still in the process of implementing these steps and cannot assure investors that these measures will significantly improve or remediate the material weaknesses described above. The material weaknesses cannot be considered remediated until the newly designed control activity operates for a sufficient period of time and management has concluded, through testing, that the control is operating effectively. We may also conclude that additional measures may be required to remediate the material weaknesses in our internal control over financial reporting, which may necessitate additional implementation and evaluation time. We will continue to assess the effectiveness of our internal control over financial reporting and take steps to remediate the known material weaknesses expeditiously.
The effectiveness of our internal control over financial reporting as of December 31, 2023 has been audited by BDO USA, P.C., an independent registered public accounting firm, as stated in their attestation report, which is included below.
Changes in internal control over financial reporting
Other than the actions taken to remediate our material weaknesses, described above, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Item 9B. Other Information.
(a) None.
(b) Insider Trading Arrangements and Policies.
There were no adoptions, modifications, or terminations by directors or officers of written trading arrangements under Exchange Act Rule 10b5-1 during the quarter ended December 31, 2023.
P3 Health Partners Inc. | 2023 Form 10-K | 114
Table of Contents
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.
None.
P3 Health Partners Inc. | 2023 Form 10-K | 115
Table of Contents
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Shareholders and Board of Directors
P3 Health Partners Inc.
Henderson, Nevada
Opinion on Internal Control over Financial Reporting
We have audited P3 Health Partners Inc.’s (the “Company’s”) internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (the “COSO criteria”). In our opinion, the Company did not maintain, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on the COSO criteria.
We do not express an opinion or any other form of assurance on management’s statements referring to any corrective actions taken by the Company after the date of management’s assessment.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the consolidated balance sheets of the Company as of December 31, 2023 and 2022, the related consolidated statements of operations, stockholders’ equity and mezzanine equity, and cash flows for the years then ended, and the related notes (collectively referred to as the “consolidated financial statements”) and our report dated March 28, 2024 expressed an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Item 9A, Management’s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit of internal control over financial reporting in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. Material weaknesses have been identified and described in management’s assessment. The material weaknesses related to the following: (1) The Company did not have adequate policies and procedures or sufficient qualified resources with appropriate technical knowledge to maintain effective internal controls over the accounting related to significant accounts and related financial statement disclosures; (2) The Company did not design and implement a sufficient risk assessment process to identify and assess risks impacting internal control over financial reporting; (3) The Company had ineffective evaluation and determination as to whether the components of internal control were present and functioning; (4) The Company did not design and implement effective information technology general controls in the areas of user access related to certain information technology systems that support the financial reporting process; (5) The Company did not maintain sufficient segregation of duties over the performance of control activities for financial close and reporting, including over the review of account reconciliations and journal entries; (6) The Company did not design and maintain effective management review controls at a sufficient level of precision over all financial statement areas; and (7) The Company did not design and maintain effective controls at a sufficient level of precision over the estimation of claims expense and payable including controls over the review of historical claims data, including the completeness and accuracy of data used to determine the financial statement amounts. These material weaknesses were considered in determining the nature, timing, and extent of audit tests applied in our audit of the 2023 financial statements, and this report does not affect our report dated March 28, 2024 on those financial statements.
P3 Health Partners Inc. | 2023 Form 10-K | 116
Table of Contents
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ BDO USA, P.C.
Las Vegas, Nevada
March 28, 2024
P3 Health Partners Inc. | 2023 Form 10-K | 117
Table of Contents
PART III
Item 10. Directors, Executive Officers and Corporate Governance.
The following table provides information regarding our executive officers and members of our board of directors (ages as of the date of this Form 10-K):
Name Age Position at P3
Principal Employment
Executive Officers
Sherif Abdou, M.D. 63 Chief Executive Officer, Director and Co-Founder Same
Amir Bacchus, M.D. 60 Chief Medical Officer, Director and Co-Founder Same
Atul Kavthekar 55 Chief Financial Officer Same
Non-Employee Directors
Mark Thierer 64 Chairman of the Board Managing Partner of AssetBlue Investment Group, an investment firm
Greg Wasson 65 Director Co-President and Founder of Wasson Enterprise, a family-based investment office
Lawrence B. Leisure 73 Director Co-Founder and a Managing Partner of Chicago Pacific Founders, a private equity fund focused on healthcare services, technology and healthcare real estate
Mary Tolan 63 Director Co-Founder and a Managing Partner of Chicago Pacific Founders, a private equity fund focused on healthcare services, technology and healthcare real estate
Greg Kazarian 61 Director Operating Partner of Chicago Pacific Founders, a private equity fund focused on healthcare services, technology and healthcare real estate
Thomas E. Price, M.D. 69 Director Director of: Triumph Orthopedics, LLC; HealthWiseFirst, LLC; Association Health Plans of America, LLC; Transformation Care Network; Botanicals Sciences, LLC; and Capital Ministries (non-profit)
Jeffrey G. Park 52 Director President of Waltz Health, a digital health company
The remaining information required by this item will be included in our definitive Proxy Statement for the 2024 Annual Meeting of Stockholders and such information is incorporated herein by reference.
Item 11. Executive Compensation.
The information required by this item will be included in our definitive Proxy Statement for the 2024 Annual Meeting of Stockholders and such information is incorporated herein by reference.
P3 Health Partners Inc. | 2023 Form 10-K | 118
Table of Contents
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
Securities Authorized for Issuance Under Equity Compensation Plans (as of December 31, 2023)
Plan category: Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants, and Rights Weighted Average Exercise Price of Outstanding Options, Warrants, and Rights (2)
Number of Securities Available for Future Issuance Under Equity Compensation Plans (excludes securities reflected in first column) (3)
Equity compensation plans approved by security holders (1)
10,671,766 $ 1.33 5,862,646
_____________________________________________
(1) Consists of the 2021 Plan.
(2) The weighted average exercise price does not include restricted stock units granted under the 2021 Plan.
(3) The number of shares of common stock reserved for issuance under the 2021 Plan will increase on the first day of each calendar year beginning on January 1, 2022 and ending on and including January 1, 2031, by a number equal to the lesser of (i) 1% of the aggregate number of shares of Class A common stock and Class V common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of Shares (as defined in the 2021 Plan) as is determined by the board of directors.
The remaining information required by this item will be included in our definitive Proxy Statement for the 2024 Annual Meeting of Stockholders and such information is incorporated herein by reference.
Item 13. Certain Relationships and Related Transactions, and Director Independence.
The information required by this item will be included in our definitive Proxy Statement for the 2024 Annual Meeting of Stockholders and such information is incorporated herein by reference.
Item 14. Principal Accountant Fees and Services.
The information required by this item will be included in our definitive Proxy Statement for the 2024 Annual Meeting of Stockholders and such information is incorporated herein by reference.
P3 Health Partners Inc. | 2023 Form 10-K | 119
Table of Contents
PART IV
Item 15. Exhibit and Financial Statement Schedules.
(a)(1) Financial Statements.
Page
Consolidated Balance Sheets
76
Consolidated Statements of Operations
77
Consolidated Statements of Stockholders’ Equity and Mezzanine Equity
78
Consolidated Statements of Cash Flows
79
Notes to Consolidated Financial Statements
81
(a)(2) Financial Statement Schedules.
Financial statement schedules are omitted because they are not applicable, not required, or because the required information is included in the consolidated financial statements or notes thereto.
(a)(3) Exhibits.
The following is a list of exhibits filed as part of this Form 10-K.
Exhibit
Number Description
Incorporated by Reference
Form File No. Exhibit Filing Date
2.1 Agreement and Plan of Merger, dated as of May 25, 2021, by and between Foresight Acquisition Corp., P3 Health Group Holdings, LLC and FAC Merger Sub LLC.
8-K 001-40033 2.1 6/1/2021
2.2 Transaction and Combination Agreement, dated as of May 25, 2021, by and among Foresight Acquisition Corp., the Merger Corps, the Blockers, Splitter and the Blocker Sellers.
8-K 001-40033 2.2 6/1/2021
2.3 First Amendment to Merger Agreement, dated as of November 21, 2021, by and among Foresight Acquisition Corp., FAC Merger Sub LLC and P3 Health Group Holdings, LLC.
8-K 001-40033 2.1 11/22/2021
2.4 Second Amendment, dated as of December 3, 2021, to the Agreement and Plan of Merger, dated as of May 25, 2021, by and among Foresight Acquisition Corp., FAC Merger Sub LLC and P3 Health Group Holdings, LLC.
8-K 001-40033 2.4 12/9/2021
2.5 The First Amendment to the Transaction and Combination Agreement between Foresight Acquisition Corp., the Merger Corps, the Blockers, Splitter and the Blocker Sellers.
8-K 001-40033 2.5 12/9/2021
3.1 Amended and Restated Certificate of Incorporation of the Company.
8-K 001-40033 3.1 12/9/2021
3.2 Amended and Restated Bylaws of the Company.
8-K 001-40033 3.1 3/12/2024
4.1 Form of Common Stock Certificate of the Company.
S-1 333-251978 4.2 1/19/2021
4.2 Warrant Agreement, dated February 9, 2021, between the Company and Continental Stock Transfer & Trust Company.
8-K 001-40033 4.1 2/16/2021
4.3 Form of Warrant Certificate of the Company.
8-K 001-40033 4.1 2/16/2021
4.4 Description of Registered Securities.
10-K 001-40033 4.4 10/21/2022
P3 Health Partners Inc. | 2023 Form 10-K | 120
Table of Contents
Exhibit
Number Description
Incorporated by Reference
Form File No. Exhibit Filing Date
4.5 Warrant Agreement, dated December 13, 2022, by and between P3 Health Partners LLC and VBC Growth SPV LLC.
8-K 001-40033 10.2 2/13/2022
4.6 Form of Common Stock Purchase Warrant, dated April 6, 2023.
8-K 001-40033 4.1 4/7/2023
4.7 Form of Pre-Funded Common Stock Purchase Warrant, dated April 6, 2023.
8-K 001-40033 4.2 4/7/2023
10.1 First Amendment to Term Loan Agreement, Termination of Management Rights Letter and Consent, dated as of December 3, 2021, by among P3 Health Group Holdings, LLC, as borrower, the subsidiary guarantors party thereto, the lenders from time to time party thereto and CRG Servicing LLC, as administrative agent and collateral agent.
8-K 001-40033 10.1 12/9/2021
10.2 Form of Subscription Agreement.
8-K 001-40033 10.2 6/1/2021
10.3 Form of Consent and Amendment to Subscription Agreement.
8-K 001-40033 10.1 11/22/2021
10.4 Registration Rights and Lock-up Agreement, dated December 3, 2021, by and among the registrant, Foresight Sponsor Group, LLC, FA Co-Investment LLC and the P3 Sellers party thereto.
8-K 001-40033 10.4 12/9/2021
10.5 P3 Health Group, LLC Amended and Restated Limited Liability Agreement, dated as of December 3, 2021, by and among P3 Health Group, LLC, the registrant and each of the other members party thereto.
8-K 001-40033 10.5 12/9/2021
10.6 Tax Receivable Agreement, dated as of December 3, 2021, by and among P3 Health Group, LLC and the members of P3 Health Group, LLC from time to time party thereto.
8-K 001-40033 10.6 12/9/2021
10.7† Form of Indemnification Agreement for directors and executive officers.
8-K 001-40033 10.7 12/9/2021
10.8† Form of Indemnification Agreement for sponsor affiliated directors.
8-K 001-40033 10.8 12/9/2021
10.9† Letter Agreement, dated November 27, 2022, by and between P3 Health Partners Inc. and Atul Kavthekar.
8-K 001-40033 10.2 12/1/2022
10.10† P3 Health Partners Inc. 2021 Incentive Award Plan.
8-K 001-40033 10.1 12/9/2021
10.11† First Amendment to the P3 Health Partners Inc. 2021 Incentive Award Plan.
10-K 001-40033 10.1 10/21/2022
10.12† Form of Restricted Stock Unit Award Agreement under the P3 Health Partners Inc. 2021 Incentive Award Plan.
8-K 001-40033 10.1 12/9/2021
10.13† Form of Stock Option Award Agreement under the P3 Health Partners Inc. 2021 Incentive Award Plan.
8-K 001-40033 10.1 12/9/2021
10.14† P3 Health Group Holdings, LLC 2017 Management Incentive Plan.
8-K 001-40033 10.2 12/9/2021
10.15† Form of Incentive Unit Award Agreement under the P3 Health Group Holdings, LLC 2017 Management Incentive Plan.
8-K 001-40033 10.2 12/9/2021
10.16 Form of Joinder and Waiver Agreement.
8-K 001-40033 10.2 12/9/2021
P3 Health Partners Inc. | 2023 Form 10-K | 121
Table of Contents
Exhibit
Number Description
Incorporated by Reference
Form File No. Exhibit Filing Date
10.17 Escrow Agreement, dated as of December 3, 2021, by and among the Company, P3 Health Group Holdings, LLC, P3 Health Group, LLC, Hudson Vegas Investment SPV, LLC, Mary Tolan and Sherif Abdou, as unitholder representatives and PNC Bank, N.A.
8-K 001-40033 10.2 12/9/2021
10.18 Repurchase Promissory Note between P3 Health Group Holdings, LLC and IHC Health Services, Inc., dated June 28, 2019.
10-K 001-40033 10.2 10/21/2022
10.19 First Amendment to Repurchase Promissory Note between P3 Health Group Holdings, LLC and IHC Health Services, Inc., dated November 19, 2020.
10-K 001-40033 10.2 10/21/2022
10.20 Second Amendment to Term Loan Agreement and First Amendment to Security Agreement, dated as of December 21, 2021, by and among P3 Health Group, LLC, as borrower, the Subsidiary Guarantors party thereto and CRG Servicing LLC, as administrative agent and collateral agent.
10-K 001-40033 10.2 10/21/2022
10.21† Employment Agreement, by and among P3 Health Partners Inc., P3 Health Group Management, LLC and Dr. Sherif Abdou.
8-K 001-40033 10.1 5/18/2022
10.22† Employment Agreement, by and among P3 Health Partners Inc., P3 Health Group Management, LLC and Dr. Amir Bacchus.
8-K 001-40033 10.2 5/18/2022
10.23† Transaction Bonus Agreement, by and among P3 Health Partners Inc., P3 Health Group Management, LLC and Dr. Sherif Abdou.
8-K 001-40033 10.3 5/18/2022
10.24† Transaction Bonus Agreement, by and among P3 Health Partners Inc., P3 Health Group Management, LLC and Dr. Amir Bacchus.
8-K 001-40033 10.4 5/18/2022
10.25† Non-Employee Director Compensation Program.
10-K 001-40033 10.3 10/21/2022
10.26 Unsecured Promissory Note, dated December 13, 2022, by and between P3 Health Partners LLC and VBC Growth SPV LLC.
8-K 001-40033 10.1 12/13/2022
10.27 Subordination Agreement, dated as of December 13, 2022, by and among CRG Servicing, LLC and VBC Growth SPV LLC.
8-K 001-40033 10.3 12/13/2022
10.28 Third Amendment to Term Loan Agreement, dated as of December 13, 2022, by and among P3 Health Group, LLC, as borrower, the Subsidiary Guarantors party thereto, the Lenders party thereto and CRG Servicing LLC, as administrative agent and collateral agent.
8-K 001-40033 10.4 12/13/2022
10.29 Securities Purchase Agreement, dated March 30, 2023, by and among P3 Health Partners Inc. and the Purchasers named therein.
8-K 001-40033 10.1 4/7/2023
10.30 Registration Rights Agreement, dated April 6, 2023, by and among P3 Health Partners Inc. and the Purchasers named therein.
8-K 001-40033 10.2 4/7/2023
10.31 *
A mendment No. 1 to Registration Rights Agreement and Waiver , dated November 8, 2023, by and among P3 Health Partners Inc. and certain stockholders pa rty thereto .
P3 Health Partners Inc. | 2023 Form 10-K | 122
Table of Contents
Exhibit
Number Description
Incorporated by Reference
Form File No. Exhibit Filing Date
10.32 Letter Agreement, dated April 6, 2023, by and among P3 Health Partners Inc., Chicago Pacific Founders GP, L.P. and Chicago Pacific Founders GP III, L.P.
8-K 001-40033 10.3 4/7/2023
10.33†
Transaction Bonus Restricted Stock Unit Agreement by and between Sherif Abdou, M.D. and P3 Health Partners Inc., dated August 4, 2023.
10-Q
001-40033 10.1 11/8/2023
10.34†
Transaction Bonus Restricted Stock Unit Agreement by and between Amir Bacchus, M.D. and P3 Health Partners Inc., dated August 4, 2023.
10-Q 001-40033 10.2 11/8/2023
10.35 Unsecured Promissory Note, by and between P3 Health Group, LLC and VBC Growth SPV 2, LLC.
8-K 001-40033 10.1 3/28/2024
10.36 Subordination Agreement, by and among P3 Health Group, LLC, CRG Servicing LLC and VBC Growth SPV 2, LLC.
8-K 001-40033 10.2 3/28/2024
10.37 Fourth Amendment to Term Loan Agreement, by and among P3 Health Group, LLC, the subsidiary guarantors party thereto, the lenders party thereto and CRG Servicing LLC.
8-K 001-40033 10.3 3/28/2024
10.38 Consent, by and between P3 Health Group, LLC and VBC Growth SPV LLC.
8-K 001-40033 10.4 3/28/2024
21.1 * List of Subsidiaries.
23.1 * Consent of Independent Registered Public Accounting Firm.
31.1 * Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 * Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 ** Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2 ** Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
97.1 *
Policy for Recovery of Erroneously Awarded Compensation.
101.INS * Inline XBRL Instance Document
101.SCH * Inline XBRL Taxonomy Extension Schema Document
101.CAL * Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF * Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB * Inline XBRL Taxonomy Extension Label Linkbase Document
P3 Health Partners Inc. | 2023 Form 10-K | 123
Table of Contents
Exhibit
Number Description
Incorporated by Reference
Form File No. Exhibit Filing Date
101.PRE * Inline XBRL Taxonomy Extension Presentation Document
104 * Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
____________________
*
Filed herewith
**
Furnished herewith
†
Indicates management contract or compensatory plan
Item 16. Form 10-K Summary.
None.
P3 Health Partners Inc. | 2023 Form 10-K | 124
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
P3 Health Partners Inc.
By: /s/ Sherif W. Abdou, M.D.
Name: Sherif W. Abdou, M.D.
Date: March 28, 2024
Title: Chief Executive Officer
(Principal Executive Officer)
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
Signature Title Date
/s/ Sherif W. Abdou, M.D.
Chief Executive Officer and Director March 28, 2024
Sherif W. Abdou, M.D. (Principal Executive Officer)
/s/ Atul Kavthekar Chief Financial Officer March 28, 2024
Atul Kavthekar (Principal Financial Officer and Principal Accounting Officer)
/s/ Mark Thierer Chairman of the Board of Directors March 28, 2024
Mark Thierer
/s/ Amir S. Bacchus, M.D.
Chief Medical Officer and Director March 28, 2024
Amir S. Bacchus, M.D.
/s/ Gregory N. Kazarian Director March 28, 2024
Gregory N. Kazarian
/s/ Lawrence B. Leisure Director March 28, 2024
Lawrence B. Leisure
/s/ Jeffrey G. Park Director March 28, 2024
Jeffrey G. Park
/s/ Thomas E. Price, M.D.
Director March 28, 2024
Thomas E. Price, M.D.
/s/ Mary A. Tolan Director March 28, 2024
Mary A. Tolan
/s/ Greg Wasson Director March 28, 2024
Greg Wasson